These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

154 related articles for article (PubMed ID: 35235189)

  • 61. Bosutinib-induced lung injury: a report of two cases and literature review.
    Watanabe N; Takaku T; Tsukune Y; Yasuda H; Ochiai T; Yamada K; Nakazawa H; Hotta S; Nishimaki T; Takagi H; Takahashi K; Komatsu N; Ando M
    Int J Hematol; 2022 Jun; 115(6):902-905. PubMed ID: 35229254
    [TBL] [Abstract][Full Text] [Related]  

  • 62. Bosutinib: a review of preclinical studies in chronic myelogenous leukaemia.
    Boschelli F; Arndt K; Gambacorti-Passerini C
    Eur J Cancer; 2010 Jul; 46(10):1781-9. PubMed ID: 20399641
    [TBL] [Abstract][Full Text] [Related]  

  • 63. Bosutinib treatment for Philadelphia chromosome-positive leukemias.
    Bethelmie-Bryan B; Lord K; Holloway S; Khoury HJ
    Future Oncol; 2014 Feb; 10(2):179-85. PubMed ID: 24490604
    [TBL] [Abstract][Full Text] [Related]  

  • 64. Bosutinib in combination with the aromatase inhibitor exemestane: a phase II trial in postmenopausal women with previously treated locally advanced or metastatic hormone receptor-positive/HER2-negative breast cancer.
    Moy B; Neven P; Lebrun F; Bellet M; Xu B; Sarosiek T; Chow L; Goss P; Zacharchuk C; Leip E; Turnbull K; Bardy-Bouxin N; Duvillié L; Láng I
    Oncologist; 2014 Apr; 19(4):346-7. PubMed ID: 24674873
    [TBL] [Abstract][Full Text] [Related]  

  • 65. Health care resource utilization in 3L + patients with chronic phase chronic myeloid leukemia receiving asciminib or bosutinib.
    Cortes JE; Rea D; Mauro MJ; Tran D; Wang P; Jadhav K; Yocolly A; Sasaki K
    J Med Econ; 2023; 26(1):915-923. PubMed ID: 37431294
    [TBL] [Abstract][Full Text] [Related]  

  • 66. Ascending single-dose study of the safety profile, tolerability, and pharmacokinetics of bosutinib coadministered with ketoconazole to healthy adult subjects.
    Abbas R; Leister C; El Gaaloul M; Chalon S; Sonnichsen D
    Clin Ther; 2012 Sep; 34(9):2011-9.e1. PubMed ID: 22884766
    [TBL] [Abstract][Full Text] [Related]  

  • 67. Cost-Effectiveness of Bosutinib for the Treatment of Adult Patients with Chronic Phase Chronic Myeloid Leukemia in the Second-Line Setting.
    Muresan B; Mamolo C; Cappelleri JC; Postma MJ; Heeg B
    Appl Health Econ Health Policy; 2021 Nov; 19(6):929-940. PubMed ID: 34250585
    [TBL] [Abstract][Full Text] [Related]  

  • 68. Successful treatment of follicular lymphoma with second-generation tyrosine kinase inhibitors administered for coexisting chronic myeloid leukemia.
    Fujiwara SI; Shirato Y; Ikeda T; Kawaguchi SI; Toda Y; Ito S; Ochi SI; Nagayama T; Mashima K; Umino K; Minakata D; Nakano H; Morita K; Yamasaki R; Kawasaki Y; Sugimoto M; Ashizawa M; Yamamoto C; Hatano K; Sato K; Oh I; Ohmine K; Muroi K; Kanda Y
    Int J Hematol; 2018 Jun; 107(6):712-715. PubMed ID: 29185155
    [TBL] [Abstract][Full Text] [Related]  

  • 69. Bosutinib in combination with the aromatase inhibitor letrozole: a phase II trial in postmenopausal women evaluating first-line endocrine therapy in locally advanced or metastatic hormone receptor-positive/HER2-negative breast cancer.
    Moy B; Neven P; Lebrun F; Bellet M; Xu B; Sarosiek T; Chow L; Goss P; Zacharchuk C; Leip E; Turnbull K; Bardy-Bouxin N; Duvillié L; Láng I
    Oncologist; 2014 Apr; 19(4):348-9. PubMed ID: 24674874
    [TBL] [Abstract][Full Text] [Related]  

  • 70. [New treatment option for patient with CML-bosutinib].
    Takahashi N
    Gan To Kagaku Ryoho; 2015 May; 42(5):563-7. PubMed ID: 26054091
    [No Abstract]   [Full Text] [Related]  

  • 71. Effect of aprepitant, a moderate CYP3A4 inhibitor, on bosutinib exposure in healthy subjects.
    Hsyu PH; Pignataro DS; Matschke K
    Eur J Clin Pharmacol; 2017 Jan; 73(1):49-56. PubMed ID: 27718000
    [TBL] [Abstract][Full Text] [Related]  

  • 72. A clinical study to examine the potential effect of lansoprazole on the pharmacokinetics of bosutinib when administered concomitantly to healthy subjects.
    Abbas R; Leister C; Sonnichsen D
    Clin Drug Investig; 2013 Aug; 33(8):589-95. PubMed ID: 23839484
    [TBL] [Abstract][Full Text] [Related]  

  • 73. Step-in dosing of bosutinib in pts with chronic phase chronic myeloid leukemia (CML) after second-generation tyrosine kinase inhibitor (TKI) therapy: results of the Bosutinib Dose Optimization (BODO) Study.
    Isfort S; Manz K; Teichmann LL; Crysandt M; Burchert A; Hochhaus A; Saussele S; Kiani A; Göthert JR; Illmer T; Schafhausen P; Al-Ali HK; Stegelmann F; Hänel M; Pfeiffer T; Giagounidis A; Franke GN; Koschmieder S; Fabarius A; Ernst T; Warnken-Uhlich M; Wolber U; Kohn D; Pfirrmann M; Wolf D; Brümmendorf TH;
    Ann Hematol; 2023 Oct; 102(10):2741-2752. PubMed ID: 37592092
    [TBL] [Abstract][Full Text] [Related]  

  • 74. Tyrosine kinase inhibitor therapy in chronic myeloid leukemia: update on key adverse events.
    Carneiro BA; Kaplan JB; Giles FJ
    Expert Rev Hematol; 2015 Aug; 8(4):457-79. PubMed ID: 25938861
    [TBL] [Abstract][Full Text] [Related]  

  • 75. [Chronic Myelogenous Leukemia].
    Hochhaus A; Eigendorff E; Ernst T
    Dtsch Med Wochenschr; 2018 Sep; 143(18):1304-1310. PubMed ID: 30199910
    [TBL] [Abstract][Full Text] [Related]  

  • 76. Bosutinib versus Placebo for Autosomal Dominant Polycystic Kidney Disease.
    Tesar V; Ciechanowski K; Pei Y; Barash I; Shannon M; Li R; Williams JH; Levisetti M; Arkin S; Serra A
    J Am Soc Nephrol; 2017 Nov; 28(11):3404-3413. PubMed ID: 28838955
    [TBL] [Abstract][Full Text] [Related]  

  • 77. The Impact of Hemodialysis and Liver Cirrhosis on the Plasma Concentrations of Tyrosine Kinase Inhibitors in a Patient with Chronic Myeloid Leukemia.
    Taniguchi Y; Takahashi N; Miura M; Hirase C; Sueda S; Espinoza JL; Rai S; Nakayama S; Serizawa K; Kumode T; Watatani Y; Morita Y; Tanaka H; Matsumura I
    Intern Med; 2020 Nov; 59(21):2745-2749. PubMed ID: 32641651
    [TBL] [Abstract][Full Text] [Related]  

  • 78. Bosutinib in the management of chronic myelogenous leukemia.
    Amsberg GK; Schafhausen P
    Biologics; 2013; 7():115-22. PubMed ID: 23674887
    [TBL] [Abstract][Full Text] [Related]  

  • 79. Effects of SLC22A2 808G>T polymorphism and bosutinib concentrations on serum creatinine in patients with chronic myeloid leukemia receiving bosutinib therapy.
    Abumiya M; Takahashi N; Takahashi S; Yoshioka T; Kameoka Y; Miura M
    Sci Rep; 2021 Mar; 11(1):6362. PubMed ID: 33737618
    [TBL] [Abstract][Full Text] [Related]  

  • 80. Effect of ketoconazole on the pharmacokinetics of oral bosutinib in healthy subjects.
    Abbas R; Hug BA; Leister C; Burns J; Sonnichsen D
    J Clin Pharmacol; 2011 Dec; 51(12):1721-7. PubMed ID: 21148045
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.